Alzheimer’s vax skirts deadly side effects

Scientific American is reporting on the successful advance of a preclinical Alzheimer's vaccine that combines small amounts of amyloid beta and interleukin-4, which is delivered in an inactivated herpes virus. In mice, the vaccine cleared amyloid beta. And researchers at Harvard say that because of the interleukin-4 the mice did not experience swelling--a dangerous side effect that thwarted earlier attempts to develop a similar vaccine.

"The problem with the previous trial of Aß vaccine was it led to a toxic response caused by activation of an inappropriate immune response," says Harvard's Michael Wolfe. "But this new vaccine sounds promising. I am most optimistic about this approach among all the things currently in trials right now." But he also acknowledges that we won't understand the long-term safety issues until large human trials are launched, which he hopes to see in three years.

- read the article in Scientific American

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

With COVID vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies with leading vaccines.

The U.K. became the first Western country to authorize a COVID-19 vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.